MediWound Ltd.

MediWound Ltd. is an integrated biopharmaceutical company specializing in next-generation enzymatic therapeutics for non-surgical tissue repair. The company develops, manufactures, and commercializes biologics that address unmet needs in severe burns, chronic and hard-to-heal wounds, and other indications. Its lead product, NexoBrid, is an FDA-approved orphan biologic for enzymatic eschar removal in deep partial and full-thickness thermal burns in adults and pediatric patients, offering a non-surgical alternative that preserves healthy tissue, accelerates healing, and reduces complications and costs. Pipeline candidates include EscharEx, an enzymatic debridement agent for chronic wounds such as venous leg ulcers, and MW005 for non-melanoma skin cancer treatment. MediWound Ltd. operates a cGMP-certified manufacturing facility in Yavne, Israel, supporting global commercialization through strategic partnerships in the U.S., Europe, Japan, Australia, and other markets. Headquartered in Yavne, Israel, the company serves hospitalized patients and wound care settings worldwide, advancing innovative solutions in the biotechnology sector.